Pravachol Low Drug Interaction Profile Deemed Favorable During OTC Review
This article was originally published in The Tan Sheet
Executive Summary
The drug interaction profile of Bristol-Myers Squibb's Pravachol may make the cholesterol-lowering agent a more attractive OTC switch candidate than Merck's Mevacor, FDA advisory committee members suggested.